HYDRAFIL®
HYDRAFIL®, is a proprietary hydrogel technology that when heated becomes a liquid that can be implanted into the nucleus of an intervertebral disc with a needle. Once it enters the body the gel incorporates with the existing nucleus and cools to form an integrated solid. This implant mimics the biomechanical properties of the natural disc and preserves spinal motion. The 1-year results published in Pain Physician report that in a 60-patient study, the HYDRAFIL® injectable hydrogel significantly reduced chronic low back pain and disability within 1 month and results were maintained through 12 months.
The burden of low back pain in the United States is immense.
52 Million
291 Million
$50 Billion
Latest News
Latest news on ReGelTec and HYDRAFIL® to treat degenerative disc disease.
ReGelTec Honored as MedTech Innovator Breakthrough Medtech Startup
ReGelTec is named among the 64 breakthrough Medtech Startups. MedTech Innovator (MTI), the world’s largest and most impactful accelerator for medical technology startups, today announced the 64 companies selected for its highly competitive 2025 Accelerator Cohort. These companies, representing the top 4% of nearly 1,500 global applicants, will participate in MTI’s flagship four-month program designed to de-risk innovation and accelerate the path to U.S. market success.
ReGelTec Receives CE Mark for HYDRAFIL® System to Treat Chronic Low Back
Clinical data show the percutaneous disc augmentation system generated significant improvements in pain and disability scores through 2-year follow-up. ReGelTec Inc., a company developing a percutaneous hydrogel implant for the treatment of chronic low back pain caused by degenerative disc disease, announced it has received CE Mark under the European Union Medical Device Regulation (MDR) for its Class III HYDRAFIL System for disc augmentation.
ReGelTec Enrolls 1st Patient in the HYDRAFIL®-D Study
ReGelTec Inc., a company developing a percutaneous hydrogel implant for the treatment of chronic low back pain caused by degenerative disc disease, announced it has treated the first patient in its HYDRAFIL-D FDA investigational device exemption (IDE) clinical trial for its HYDRAFIL® System for disc augmentation.
